Piper Sandler Issues Positive Forecast for Enfusion (NYSE:ENFN) Stock Price

Enfusion (NYSE:ENFN) had its price objective increased by stock analysts at Piper Sandler from $10.00 to $11.50 in a report released on Monday,Benzinga reports. The firm currently has a “neutral” rating on the stock. Piper Sandler’s price objective points to a potential upside of 8.18% from the company’s current price.

Separately, Stifel Nicolaus boosted their price target on shares of Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, Enfusion has a consensus rating of “Hold” and an average price target of $10.25.

Enfusion Trading Up 1.5 %

ENFN stock opened at $10.63 on Monday. The firm has a 50 day moving average of $9.70 and a 200-day moving average of $9.00. The firm has a market capitalization of $1.37 billion, a P/E ratio of 265.82, a price-to-earnings-growth ratio of 3.98 and a beta of 0.97. Enfusion has a 12 month low of $7.52 and a 12 month high of $11.38.

Insider Transactions at Enfusion

In other news, COO Neal Pawar sold 21,801 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.03, for a total value of $218,664.03. Following the completion of the transaction, the chief operating officer now directly owns 1,143,544 shares in the company, valued at approximately $11,469,746.32. This represents a 1.87 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 36.44% of the company’s stock.

Institutional Trading of Enfusion

Hedge funds have recently bought and sold shares of the company. Arizona State Retirement System bought a new position in Enfusion during the second quarter valued at approximately $86,000. Harbor Capital Advisors Inc. grew its holdings in shares of Enfusion by 12.4% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after purchasing an additional 1,315 shares during the last quarter. Belvedere Trading LLC purchased a new position in Enfusion in the 3rd quarter worth $114,000. Paloma Partners Management Co bought a new stake in Enfusion in the third quarter worth $157,000. Finally, The Manufacturers Life Insurance Company lifted its stake in Enfusion by 27.7% in the second quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock worth $167,000 after purchasing an additional 4,239 shares during the last quarter. Institutional investors own 81.05% of the company’s stock.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.